Provectus Biopharmaceuticals, Inc. (NYSEMKT:PVCT) held a conference call on 19 June Thursday to discuss the outline of the Company’s planned phase 3 study of PV-10 in the treatment of melanoma and developments in the use of PV-10 in other cancer indications including PV-10 in combination as appropriate. Provectus Biopharmaceuticals Inc. (NYSEMKT:PVCT) weekly performance is -21.71%. On last trading day company shares ended up $1.01. Analysts mean target price for the company is $3.50. Provectus Biopharmaceuticals Inc. (NYSEMKT:PVCT) distance from 50-day simple moving average (SMA50) is -48.01%.
22nd Century Group, Inc. (NYSEMKT:XXII) on 29 may announced that its subsidiary, Goodrich Tobacco Company LLC, signed a letter of intent with Orion, a cigarette manufacturer based in Poland, to contract manufacture the Company’s proprietary tobacco products to be distributed in the European Union. 22nd Century Group Inc. (NYSEMKT:XXII) shares fell -6.13% in last trading session and ended the day on $3.52. XXII gross Margin is 92.20% and its return on assets is -370.50%.22nd Century Group Inc. (NYSEMKT:XXII) quarterly performance is -0.28%.
On June 6, 2014, the Board of Directors of BioLife Solutions, Inc. (NASDAQ:BLFS) established June 13, 2014 as the record date for the Company’s 2014 annual meeting of stockholders. The annual meeting is scheduled to be held at 9:00 a.m. on August 6, 2014 at 3303 Monte Villa Parkway, Suite 310, Bothell, Washington 98021. BioLife Solutions Inc. (NASDAQ:BLFS) shares moved down -17.36% in last trading session and was closed at $2.00, while trading in range of $2.00 – $2.47. BioLife Solutions Inc. (NASDAQ:BLFS) year to date (YTD) performance is -76.19%.
Analysts at JMP Securities initiated coverage on shares of Cerulean Pharma Inc. (NASDAQ:CERU) in a research note on Tuesday, May 6th. They set an “outperform” rating and a $14.00 price target on the stock. Cerulean Pharma Inc. (NASDAQ:CERU) ended the last trading day at $5.81. Company weekly volatility is calculated as 8.35% and price to cash ratio as 13.75.Cerulean Pharma Inc. (NASDAQ:CERU) showed a negative weekly performance of -16.16%.
On June 6, 2014, Robert Nelsen, a director of Fate Therapeutics, Inc. (NASDAQ:FATE), concluded his term on the Board of Directors of the Company and all committees thereof and did not stand for re-election at the Company’s 2014 Annual Meeting of Stockholders. Mr. Nelsen previously served on the Compensation Committee. The decision of Mr. Nelsen to retire from the Board of Directors did not involve any disagreement with the Company. Fate Therapeutics Inc. (NASDAQ:FATE) weekly performance is -11.16%. On last trading day company shares ended up $6.21. Analysts mean target price for the company is $14.50. Fate Therapeutics Inc. (NASDAQ:FATE) distance from 50-day simple moving average (SMA50) is -10.59%.
Leave a Reply